Serum Trefoil Factor 3 as a Potential Noninvasive Marker of Disease Activity and Endoscopic Remission in Ulcerative Colitis: A Prospective Longitudinal Study
Gastrointestinal Disorders · 01.11.2026 · 8 (4) · 72
DOI: 10.3390/gidisord8040072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastrointestinal Disorders, online erschienen am 01.11.2026. Verfasst von Shady Ibrahim Elhefnawy und 6 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Endoscopy is an invasive and expensive tool for evaluating ulcerative colitis (UC). Noninvasive biomarkers may complement endoscopy.
Aim
To evaluate serum Trefoil Factor 3 (TFF3) as a potential noninvasive biomarker for UC activity and remission.
Methods
This is a prospective longitudinal observational study including patients with UC. Disease activity was assessed by the Lichtiger Clinical Activity Index (LCAI) and UC Endoscopic Index of Severity (UCEIS). Clinical and endoscopic remission were defined as LCAI ≤ 3 and UCEIS ≤ 1, respectively. Serum TFF3 and fecal calprotectin were measured to evaluate the within-patient change in serum TFF3 from active disease to remission.
Results
Follow-up of 75 patients with active UC showed that TFF3 was significantly higher in active UC than in remission and controls (9.85 ± 2.17 vs. 5.66 ± 2.42 vs. 2.64 ± 0.99 ng/mL; p < 0.001). TFF3 correlated positively with LCAI, UCEIS, and fecal calprotectin (p < 0.001). In multivariable analysis, fecal calprotectin was independently associated with baseline TFF3 concentrations. TFF3 discriminated active disease from remission (AUC = 0.902; 95% CI 0.869–0.936, patient-level cluster bootstrap), with 88.0% sensitivity and 73.3% specificity at an exploratory Youden-optimal cutoff of >7.27 ng/mL derived in the same cohort. Fecal calprotectin had an AUC of 0.915 (95% CI 0.877–0.950; difference −0.013, 95% CI −0.049 to 0.026). Adding TFF3 to a calprotectin model increased the AUC only slightly (+0.016, 95% CI 0.001–0.038).
Conclusions
In this two-center cohort, serum TFF3 was associated with clinical, endoscopic, and fecal calprotectin-based measures of disease activity and decreased after remission, although it remained higher than in healthy controls. TFF3 may be a possible complementary noninvasive biomarker, but it is not a replacement for endoscopic evaluation, and its cutoff requires external validation before clinical use.
Zitieren
APA
Elhefnawy, S. I., Ghazy, A. A., Amer, I. F., Fouda, M. H., Shady, E., Shatara, S. A., & Shatara, Y. A. (2026). Serum Trefoil Factor 3 as a Potential Noninvasive Marker of Disease Activity and Endoscopic Remission in Ulcerative Colitis: A Prospective Longitudinal Study. Gastrointestinal Disorders, 8(4), 72. https://doi.org/10.3390/gidisord8040072
Vancouver
Elhefnawy SI, Ghazy AA, Amer IF, Fouda MH, Shady E, Shatara SA, et al. Serum Trefoil Factor 3 as a Potential Noninvasive Marker of Disease Activity and Endoscopic Remission in Ulcerative Colitis: A Prospective Longitudinal Study. Gastrointestinal Disorders. 2026;8(4):72. doi:10.3390/gidisord8040072
BibTeX
@article{Elhefnawy2026,
author = {Elhefnawy, Shady Ibrahim and Ghazy, Amany A. and Amer, Ibrahim Fathi and Fouda, Mohamed H. and Shady, Ebtesam and Shatara, Salma A. and Shatara, Youssef A.},
title = {Serum Trefoil Factor 3 as a Potential Noninvasive Marker of Disease Activity and Endoscopic Remission in Ulcerative Colitis: A Prospective Longitudinal Study},
journal = {Gastrointestinal Disorders},
year = {2026},
volume = {8},
number = {4},
pages = {72},
doi = {10.3390/gidisord8040072}
}
EUVIMED